Aquestive Therapeutics, Inc. AQST Total costs & expenses
Total costs & expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s total costs & expenses?
- Aquestive Therapeutics, Inc. (AQST) reported total costs & expenses of $18.65M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s total costs & expenses changed year-over-year?
- Aquestive Therapeutics, Inc.'s total costs & expenses decreased by 33.6% year-over-year, from $28.09M to $18.65M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s total costs & expenses?
- Over 3 years (2022 to 2025), Aquestive Therapeutics, Inc.'s total costs & expenses has grown at a 8.8% compound annual growth rate (CAGR), from $89.75M to $115.6M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating and non-operating costs incurred by the company during a reporting period. It encompasses the cost of goods sold, research and development expenditures, and selling, general, and administrative expenses. Monitoring this figure is essential for assessing the company's overall cost structure and operational efficiency relative to revenue generation.